Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.

Distilling that complexity into a handful of trends has been no small task. What follows is not a definitive forecast, but ...

AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon ​to announce agreements ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...

UnitedHealth Group (UNH 1.05%) and Eli Lilly (LLY +1.45%) are two of the largest and most powerful healthcare companies in ...

Eli Lilly might have a solution for patients trying to decide whether to stay on obesity treatments forever. A study showed ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

"Scandalous unveiling on the 'Presidential Walk of Fame' sends shockwaves through Washington. You won't believe what Trump's ...

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.